|
WO2020229369A1
|
|
Daptomycin aqueous formulations
|
|
EP3620462A1
|
|
Process for the preparation of caspofungin
|
|
CN111093625A
|
|
Daptomycin formulations
|
|
WO2018073269A1
|
|
Liquid formulations of daptomycin
|
|
MX2018013584A
|
|
Stabilized glycopeptide antibiotic formulations.
|
|
WO2017037232A1
|
|
Anidulafungin formulations
|
|
WO2016166103A1
|
|
Polymyxin derivatives
|
|
WO2016071495A1
|
|
Glycopeptide compositions
|
|
EP3718571A1
|
|
Compositions
|
|
AU2015326847A1
|
|
Inhalation device
|
|
EP3166960A1
|
|
Low substituted polymyxins and compositions thereof
|
|
AU2015233583A1
|
|
New polymorphs and new solid states of Tiacumicin B
|
|
AU2014368566A1
|
|
Process for the preparation of Tiacumicin
|
|
WO2015075221A1
|
|
Container system for intravenous therapy
|
|
TW201522364A
|
|
Characterization of colistimethate sodium (CMS)
|
|
EP3003273A1
|
|
A method for stabilizing tigecycline
|
|
WO2014108474A1
|
|
Voriconazole inclusion complexes
|
|
CA2895910A1
|
|
Polymyxins, compositions, methods of making and methods of use
|
|
WO2014032956A1
|
|
Tigecycline formulations
|
|
WO2013164102A1
|
|
Process for preparation of ixabepilone and intermediates useful in said process.
|
